Session » (1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1827

Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device

Abstract Number: 1828

Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission

Abstract Number: 1829

Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome

Abstract Number: 1830

Exploring Psychosocial Characteristics of Youth with Chronic Pain Across Gender Identities

Abstract Number: 1831

Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia

Abstract Number: 1832

Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital

Abstract Number: 1833

Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

Abstract Number: 1834

Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort

Abstract Number: 1835

A Survey on Fibromyalgia-Related Knowledge Among Internal Medicine Residents

Abstract Number: 1836

Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium

Abstract Number: 1837

Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia

Abstract Number: 1838

The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility

Abstract Number: 1839

Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.